Research Studies

Renal Disease Research Institute (RDRI) is a research entity affiliated with Dallas Nephrology Associates. For over 45 years, Dallas Nephrology Associates has been caring for patients with kidney disease, hypertension, transplants and complicated electrolyte disorders. The Research Institute allows us to conduct clinical trials that will improve our future ability to treat kidney disease and give our patients the opportunity to receive cutting-edge therapy. At RDRI, there is significant ethical oversight of this entity through RDRI’s Board of Managers and Scientific Review Committee.

Choosing to participate in a study is an important personal decision. Are you interested in participating in a study? Talk with your doctor and family members or friends about deciding to join a study.

Patients with FSGS & treatment resistant minimal change in disease (Goldfinch)

Protocol Name: Placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GFB-887, a TRPC5 channel inhibitor in patients with focal segmental glomerulosclerosis, and treatment-resistant minimal change disease (Goldfinch)

Indication: Patients with FSGS & treatment-resistant minimal change in disease

PI: Dr. Venkata Yalamanchilli

Location: Charlton Office - 2651 Bolton Boone Desoto, TX 75115

Treatment of Primary IgA nephropathy Patients (Applause)

Protocol Name: A multi-center, randomized, double-blind, placebo-controlled, parallel-group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients (Applause)

Indication: Treatment of Primary IgA nephropathy Patients

PI: Dr. Anupkumar Shetty

Location: Charlton office- 2651 Bolton Boone Desoto, TX 75115

Patients requiring dialysis, needing creation of AV fistula (BARD)

Protocol Name: A Prospective, Multi-Center Clinical Study of the BD^®WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis (BARD)

Indication: Patients requiring dialysis, needing creation of AV fistula

PI: Dr. Neghae Mawla, MD

Location: 4401 Tradition Trail Plano, Texas 75093

Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

Protocol Name: Novo-Nordisk ZEUS Study- Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

Indication: Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

Primary Investigator:
Dr. Ankit Mehta

Location:
1420 Viceroy Drive, Dallas, TX 75235

Treatment of Venous Outflow Circuit Stenosis or Occlusion in Hemodialysis Patients (Merit Wave)

Protocol Name: Prospective, Randomized, Controlled, Multicenter Study Comparing the Merit WRAPSODYTM Endovascular Stent Graft to Percutaneous Transluminal Angioplasty for Treatment of Venous Outflow Circuit Stenosis or Occlusion in Hemodialysis Patients (Merit Wave Study)(Plano)

Indication: Treatment of Venous Outflow Circuit Stenosis or Occlusion in Hemodialysis Patients

Primary Investigators:
Dr. Neghae Mawla, MD (Plano)
Dr. Jeffrey Siegel, MD (Dallas)

Locations:
Plano Vascular-4401 Tradition Trail Plano, Texas 75093
Dallas Vascular – 3604 Live Oak St. Suite 300, Dallas, Texas, 75204

Proteinuric Glomerular Disease – IgAN, FSGS, Alport Syndrome, Diabetic Kidney disease (The AFFINITY Study)

Protocol Name: A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)

Indication: Proteinuric Glomerular Disease – IgAN, FSGS, Alport Syndrome, Diabetic Kidney disease

Primary Investigator: Dr. Akinwande Akinfolarin

Location: Landry office – 411 N. Washington Ave Suite 7000, Dallas, TX 75246

Patients with IgA Nephropathy at Risk of Progressive loss of renal function (The ALIGN Study)

Protocol Name: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)

Indication: Patients with IgA Nephropathy at Risk of Progressive loss of renal function

Primary Investigator: Dr. Akinwande Akinfolarin

Location: Landry office – 411 N. Washington Ave Suite 7000, Dallas, TX 75246

Treatment for Patients with Fabry Disease (Fabry)

Protocol Name: Expanded Access Treatment with Open-Label Pegunigalsidase Alfa for Fabry Patients (Fabry)(New)

Primary Investigator: Dr. Ankit Mehta

Indication: Treatment for Patients with Fabry Disease

Location: Corporate office -1420 VICEROY DRIVE DALLAS, TX 75235

Autosomal dominant polycystic kidney disease – PKD (Falcon)

Protocol Name: A phase 3 trial of the efficacy and safety of bardoxolone methyl in patients with autosomal dominant polycystic kidney disease. (Falcon)

Indication: Autosomal dominant polycystic kidney disease – PKD

PI: Dr. Ankit Mehta

Location: Corporate office -1420 VICEROY DRIVE DALLAS, TX 75235

Immunoglobin nephropathy – IgA (Omeros)

Protocol Name: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS-IGAN). (Omeros)

Indication: Immunoglobin nephropathy – IgA

PI: Dr. Akinwande Akinfolarin

Location: Landry Office – 411 N. WASHINGTON AVENUE SUITE 7000 DALLAS, TX 75246

Chronic active antibody-mediated rejection in kidney transplant recipients (Imagine)

Protocol Name: Clinical study protocol a pivotal phase 3 trial to evaluate the safety and efficacy of clazakizumab for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients (Imagine)

Indication: Chronic active antibody-mediated rejection in kidney transplant recipients

PI: Dr. Bernard Fischbach

Location: Corporate office – 1420 VICEROY DRIVE DALLAS, TX 75235

Treatment of BK Viremia in Kidney Transplant Recipients (Amplyx)

Protocol Name: A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients (Amplyx)